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RESPONSE TO LETTERReply to Letter: ‘‘A
Different Approach to the
Use of C-reactive Protein
and Procalcitonin in
Postoperative Infectious
Complications’’
Reply:
We would like to thank Francisco JavierMedina-Fernandez and Cesar Diaz-
Lopez1 for their insightful and thoughtful
considerations about our article ‘‘Procalcito-
nin Reveals Early Dehiscence in Colorectal
Surgery: the PREDICS Study.’’ In the aim to
analyze negative and positive predictive val-
ues (NPVand PPV) for anastomotic leak (AL)
of C-reactive protein (CRP) and procalcitonin
(PCT), we divided our study population in
three groups: patients with AL, with compli-
cations other than AL, and with no compli-
cations. Effectively, within the patients with
‘other complications,’ we did not distinguish
between infectious and noninfectious compli-
cations. Therefore, with the purpose of over-
coming this bias, we reanalyzed the data.
As shown in Table 2 of our article,1 a
total of 92 patients (18.2%) had a postoperative
complication, 28 of them (5.6%) anastomotic
leak and 83 (16.4%) ‘other’ complication.
Between the latter 83 patients, 33 had an
infective (for example, pneumonia, wound
infection, and urinary tract infection) and 50
had a noninfective problem, such as bleeding,
pulmonary embolism, or myocardial infarc-
tion. It is to note that we registered a total of 68
noninfective complications, having 18 patients
with more than one complication such as
profuse bleeding and myocardial infarction
or renal failure at the same time. In our
analysis, patients having AL and other com-
plications have been included in the AL group.
Similarly, also patients having both infective
and non-infective complication have been con-
sidered in the infective group. Using ANOVA
with log10-transformed data and Tukey HSD
post hoc comparisons, we did not find statisti-
cally significant differences between the two
subgroups (infective complications but not AL
vs other noninfective complications) regarding
mean CRP and PCT values, except for CRP in
third post-operative day (POD) (P ¼ 0.048).
Moreover, using logistic regression models to
predict anastomotic leak, receiver-operating-
characteristic curve for biomarkers are very
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regarding the noninfective other compli-
cations, area under the curve (AUC) for PCT
and CRP are respectively 0.743 and 0.783
(third POD) and 0.753 and 0.835 in fifth
POD. When we use both biomarkers together,
AUC is 0.826 in third and 0.827 in fifth POD.
In the other infective complications, AUC for
PCTand CRP are respectively 0.631 and 0.593
(third POD) and 0.729 and 0.743 in fifth POD.
Interestingly, we also didn’t find any
statistically significant differences between
patients undergoing laparoscopic (group A)
or open (group B) colorectal resection from
cancer. In fact, between the 504 patients
undergoing elective colorectal surgery, for
malignant diseases, we registered 28
(5.6%) anastomotic leaks, 13 in Group A
and 15 in Group B. In third POD, mean
PCT values in patients undergoing laparo-
scopic surgery were lower compared with the
laparotomic group, in the AL group, in the
other complications group and in the ‘no
complication’ group (4.24 vs 4.66 ng/mL,
2.12 vs 2.07 ng/mL, and 1.09 vs 1.14 ng/
mL, respectively) but not in a statistically
significant way (P ¼ 0.99). Also in fifth
POD, mean PCT values of patients with leak
of Group A were lower compared with Group
B (3.33 vs 5.02), but not in a statistically
significant way (P ¼ 0.98).
Moreover, to have an homogeneous
population, and differently from our prelimi-
nary study,2 we deliberately excluded all
emergency procedures, avoiding all perfo-
rated and acutely infected patients, and
included only elective cancer patients.
Regarding the reported disparities of
CRP values, our recent study1 showed similar
results to the IMACORS study, also newly
published on this journal.3 In fact, Facy et al3
used mg/L as unit of measure and we employed
mg/dL; so their median CRP values in third
POD for patients with infectious complications
are very similar compared with ours (16.8 mg/
dL for IMACORS vs 22 mg/dL for PREDICS).
On the other hand, there are some disparities
regarding PCT; in third POD median values in
AL patients are 1.42 ng/mL for IMACORS
versus 4.10 ng/mL in PREDICS. Conversely
to PREDICS, in the IMACORS study also
patients with diverticular disease (11.6%) and
with inflammatory bowel disease (2.2%) have
been recruited, so PCT is expected to be higher.
Moreover, in PREDICS, 75% of patients under-
went laparoscopic surgery versus nearly 30% in
IMACORS, and this is another reason we
would expect IMACORS procalcitonin levels
to be higher, not lower. Nonetheless, would be
very interesting to deeply understand the
reasons of these disparities. It is to note that
in both studies the same measuring system has
been used (Brahms PCT Kryptor, Termo-
Fischer Scientific, Hennigsdorf, Germany).
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er Health, Inc. Unauthorized repMoreover, we still think that PCT, with
its earlier peak in first POD, might give a
better help than CRP that peaks in second
POD, because of early patients discharge
protocols (quite often in third or in fourth
POD) with increasing diffusion of laparo-
scopic and minimally invasive surgery.4
It would be also interesting to know if
these biomarkers are working well in other
surgical oncological fields, with appropriate
studies, such as pancreatic cancer and stomach
cancer. Currently there are two ongoing trials
in our Institution about these topics.
The authors in their Letter also pro-
pose a new approach using patient’s personal
CRP values in second POD and comparing it
with the biomarkers in the day of the sus-
pected complication, as already published in
their recent study, and suggesting to apply
this protocol to PCT.5 In literature has been
reported that postoperative values of CRP in
patients with no complications could be
influenced by the surgical procedure and
personal variability.6,7 We think that the idea
of using each patients threshold is brilliant,
but, instead of remeasuring the biomarker
when the complication is already suspected,
perhaps it can be done before patients dis-
charge to make it safer or to keep the patient
for further studies.
Leaving on a side the discussions
about different cuts-off and different methods
of making the biomarkers measurement more
efficient in predicting complications, the
message that should come up is: biomarkers
can help the surgeon in his/her daily practice,
improving patients outcomes.
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